Neorx Corporation

Noerx Corporation

Peter G Anderson

John M Reno

David John Grainger

James C Metcalfe

Lawrence L Kunz

Peter L Weissberg

Richard A Klein

Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent. Also discussed are mechanisms for in vivo vascular smooth muscle cell proliferation modulation, agents that impact those mechanisms and protocols for the use of those agents.

Therapeutic inhibitor of vascular smooth muscle cells

Growing community of inventors

Birmingham, AL, United States of America

Peter G Anderson